Asset profile
Cannabidiol (Kanbis)
Small molecule
Evidence outlook · lead readout
NCT07651930 · Parkinson's Disease (PD)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07651930: Patients were randomized and the study was double-blinded, using validated anxiety and depression symptom scales as the primary measures, which are solid design features. However, only 27 patients were split across three dose groups, there was no placebo-free (non-CBD) comparison arm, and no results have been posted yet, so no conclusion about effect can currently be drawn.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.